Leading global health care products company,
Covidien plc
(
COV
), has offered its support to a non-governmental organization
called the Brazilian Stroke Network ("BSN") for spreading awareness
about stroke prevention and cure in Brazil. Since ischemic stroke
is the most common cause of death in the Latin American nation,
Covidien promised to provide unlimited educational grant to the
organization.
Covidien is expanding its footprint in emerging markets and
boosting market share in core segments through investments in sales
and marketing infrastructure. Management at the company's Vascular
Therapies business believes that this novel educational program by
the BSN in collaboration with other Brazilian medical societies and
the Ministry of Health can be used as a model for other nations as
well.
BSN will offer a new course, "Stroke Prevention and Treatment in
Brazil - Pre-hospital, Hospital Care and Basic Health Care", to
primary care professionals, stroke centers and emergency medical
services in Brazil with the help of the grant provided by Covidien.
The course is designed to train neurologists across the country in
the best stroke treatments available. The course thus aims to
increase the number of patients benefiting from the advanced
treatment.
BSN strongly believes that Covidien's contribution to their
organization will help Brazil's medical association to further
penetrate into the interiors of the country and educate the poorer
illiterate masses. The organization has teamed up with the
Brazilian Neurology Society, Brazilian Medical Association and the
Brazilian Stroke Society to work on the course and help Brazil's
Ministry of Health to effectuate a new stroke
policy.
Built to develop ways to control the number of deaths from
stroke, BSN along with the Brazilian Academy of Neurology and the
Brazilian Stroke Society were awarded the first prize by the World
Stroke Organization for their invaluable efforts to spread
awareness across the country.
Covidien is an international medical technology major with a
rich history of developing high-quality products in a
cost-effective manner. It competes with
Johnson & Johnson
(
JNJ
),
Becton Dickinson
(
BDX
) and
C.R. Bard
(
BCR
), among others.
However, sustained pricing/procedure volume pressure represents
a headwind. We are currently Neutral on the stock, supported by a
short-term Zacks #3 Rank (Hold).
BARD C R INC (BCR): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis
Report
COVIDIEN PLC (COV): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis
Report
To read this article on Zacks.com click here.
Zacks Investment
Research